Patients with chronic heart failure exhibited a pronounced loss of angiomiR-126 and -130a in angiogenic EOCs and circulating CD34(+) cells, which limited their cardiac repair capacity.
Observational (n=80)
Does miR-126 mimic transfection improve the cardiac neovascularization and functional repair capacity of angiogenic EOCs from patients with chronic heart failure?
Reduced miR-126 expression in angiogenic EOCs from CHF patients limits their cardiac repair capacity, which can be restored by miR-126 mimic transfection.
BACKGROUND: MicroRNAs are key regulators of angiogenic processes. Administration of angiogenic early outgrowth cells (EOCs) or CD34(+) cells has been suggested to improve cardiac function after ischemic injury, in particular by promoting neovascularization. The present study therefore examines regulation of angiomiRs, microRNAs involved in angiogenesis, in angiogenic EOCs and circulating CD34(+) cells from patients with chronic heart failure (CHF) and the role for their cardiac repair capacity. METHODS AND RESULTS: Angiogenic EOCs and CD34(+) cells were isolated from patients with CHF caused by ischemic cardiomyopathy (n=45) and healthy subjects (n=35). In flow cytometry analyses, angiogenic EOCs were largely myeloid and positive for alternatively activated M2 macrophage markers. In vivo cardiac neovascularization and functional repair capacity were examined after transplantation into nude mice with myocardial infarction. Cardiac transplantation of angiogenic EOCs from healthy subjects markedly increased neovascularization and improved cardiac function, whereas no such effect was observed after transplantation of angiogenic EOCs from patients with CHF. Real-time polymerase chain reaction analysis of 14 candidate angiomiRs, expressed in angiogenic EOCs, revealed a pronounced loss of angiomiR-126 and -130a in angiogenic EOCs from patients with CHF that was also observed in circulating CD34(+) cells. Anti-miR-126 transfection markedly impaired the capacity of angiogenic EOCs from healthy subjects to improve cardiac function. miR-126 mimic transfection increased the capacity of angiogenic EOCs from patients with CHF to improve cardiac neovascularization and function. CONCLUSIONS: The present study reveals a loss of angiomiR-126 and -130a in angiogenic EOCs and circulating CD34(+) cells from patients with CHF. Reduced miR-126 expression was identified as a novel mechanism limiting their capacity to improve cardiac neovascularization and function that can be targeted by miR-126 mimic transfection.
Jakob et al. (Thu,) conducted a observational in Chronic heart failure (n=80). Chronic heart failure vs. Healthy subjects was evaluated on Expression of angiomiR-126 and -130a in angiogenic EOCs and circulating CD34(+) cells. Patients with chronic heart failure exhibited a pronounced loss of angiomiR-126 and -130a in angiogenic EOCs and circulating CD34(+) cells, which limited their cardiac repair capacity.